

# CDK9-IN-2

**Catalog No: tcsc1252** 

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Specifications

#### CAS No:

1263369-28-3

#### Formula:

 $\mathsf{C_{23}H_{25}CIFN_{5}}$ 

Pathway:

Cell Cycle/DNA Damage

#### **Target:**

CDK

**Purity / Grade:** 

## Solubility:

10 mM in DMSO

#### **Observed Molecular Weight:**

425.93

### **Product Description**

CDK9-IN-2 is a special cyclin-dependent kinase 9 (**CDK9**) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an **IC**<sub>50</sub>


Copyright 2021 Taiclone Biotech Corp.



of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.

IC50 & Target: IC50: 5 nM (CDK9, in H929 multiple myeloma cell line), 7 nM (CDK9, in A2058 skin cell line)<sup>[1]</sup>

*In Vitro:* CDK9-IN-2 (200 nM) reduces the expression of MEPCE indicating that MEPCE is a pharmacodynamic (PD) marker for any CDK9 inhibitor. The expression of MCL1 protein is reduced 2 hours after treatment and is further reduced after 16 hour exposure to CDK9-IN-2 (500 nM)<sup>[1]</sup>.



Copyright 2021 Taiclone Biotech Corp.